Systemic fungal infections pose a serious clinical problem. Treatment options are limited,
and antifungal drug resistance is increasing. In addition, a substantial proportion of patients …

Invasive candidiasis is an important health-care-associated fungal infection that can be
caused by several Candida spp.; the most common species is Candida albicans, but the …

Yeasts occur in all environments and have been described as potent antagonists of various
plant pathogens. Due to their antagonistic ability, undemanding cultivation requirements …

The development of antimicrobial drug resistance among pathogenic bacteria and fungi is
one of the most significant health issues of the 21st century. Recently, advances in …

The need for new antifungal agents is undeniable. Current therapeutic choices for the
treatment of invasive fungal infections are limited to three classes of drugs. Most used …

In humans, microbial cells (including bacteria, archaea, and fungi) greatly outnumber host
cells. Candida albicans is the most prevalent fungal species of the human microbiota; this …

The use of antifungal drugs in the therapy of fungal diseases can lead to the development of
antifungal resistance. Resistance has been described for virtually all antifungal agents in …

Since the dawn of civilization, it has been understood that pathogenic microorganisms
cause infectious conditions in humans, which at times, may prove fatal. Among the different …

CYP51 (Erg11) belongs to the cytochrome P450 monooxygenase (CYP) superfamily and
mediates a crucial step of the synthesis of ergosterol, which is a fungal-specific sterol. It is …

The increasing resistance of pathogen fungi poses a global public concern. There are
several limitations in current antifungals, including few available fungicides, severe toxicity …